Claims
- 1. A method for agonizing or antagonizing a multimeric receptor comprising contacting the multimeric receptor with a non-antibody multimeric receptor ligand.
- 2. The method of claim 1 wherein the multimeric receptor is a dimeric receptor.
- 3. The method of claim 2 wherein the dimeric receptor is homodimeric.
- 4. The method of claim 3 wherein the non-antibody multimeric receptor ligand is homodimeric.
- 5. The method of claim 2 wherein the dimeric receptor is heterodimeric.
- 6. The method of claim 5 wherein the non-antibody multimeric receptor ligand is heterodimeric.
- 7. The method of claim 2 wherein the dimeric receptor is a hematopoietic growth factor receptor.
- 8. The method of claim 2 wherein the dimeric receptor is erythropoietin receptor, granulocyte-colony-stimulating factor receptor, macrophage-colony stimulating factor receptor, tissue growth factor α receptor, epidermal growth factor receptor, neu receptor, growth hormone receptor, prolactin receptor, placental lactogen receptor, stem cell factor receptor, tissue necrosis factor α receptor, tissue necrosis factor β receptor, fas receptor, CD40 receptor or CD27 receptor.
- 9. The method of claim 2 wherein the dimeric receptor is platelet-derived growth factor receptor, insulin receptor, insulin-like growth factor-l receptor, insulin-like growth factor-2 receptor or relaxin receptor.
- 10. The method of claim 2 wherein the dimeric receptor is granulocyte-macrophage colony stimulating factor receptor, interleukin-3 receptor, interleukin-5 receptor, interleukin-6 receptor, oncostatin M receptor, ciliary neurotropic factor receptor, leukemia inhibitory factor receptor, nerve growth factor receptor, fibroblast growth factor receptor, interleukin-4 receptor, interleukin-13 receptor, interferon α receptor, interferon β receptor, interferon γ receptor, TGF β1,2 receptor or interleukin-12 receptor.
- 11. The method of claim 1 wherein the multimeric receptor is a trimeric receptor.
- 12. The method of claim 11 wherein the trimeric receptor is heterotrimeric.
- 13. The method of claim 12 wherein the trimeric receptor is interleukin-2 receptor.
- 14. The method of claim 12 wherein the trimeric receptor is tissue necrosis factor receptor.
- 15. A method for identifying agonists and antagonists of multimeric receptors comprising the steps of:
a) contacting a multimeric receptor with non-antibody multimeric receptor ligand candidates; and b) selecting ligand candidates which bind to the receptor.
- 16. Multimeric receptor ligands identified by the method of claim 15.
- 17. Isolated non-antibody multimeric receptor agonists.
- 18. Isolated non-antibody multimeric receptor antagonists.
- 19. The isolated non-antibody multimeric receptor agonists or antagonists of claims 17 or 18 comprising a disubstituted spacer having the formula (I):
- 20. The isolated non-antibody multimeric receptor agonists or antagonists of claim 19 wherein R is
14
- 21. The isolated non-antibody multimeric receptor agonists or antagonists of claims 17 or 18 comprising a trisubstituted spacer having the formula (II):
15
- 22. The isolated non-antibody multimeric receptor agonists or antagonists of claim 21 wherein R is
19
- 23. The isolated non-antibody multimeric receptor agonists or antagonists of claim 21 wherein Q is N; 1,3,5-phenyl and
20
- 24. A method for making non-antibody multimeric receptor ligands comprising the steps of:
a) reacting a bifunctional monomer bound to a solid support with a receptor binding moiety to form a reaction product; and b) cleaving the reaction product from the solid support, wherein the two functional groups are identical and symmetrically placed after cleavage.
RELATED APPLICATIONS
[0001] This application claims the benefit of U.S. Provisional Application No. 60/030,391, filed Nov. 5, 1996.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60030391 |
Nov 1996 |
US |
Continuations (1)
|
Number |
Date |
Country |
Parent |
08963835 |
Nov 1997 |
US |
Child |
09804852 |
Mar 2001 |
US |